Trial Outcomes & Findings for Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001) (NCT NCT00543387)
NCT ID: NCT00543387
Last Updated: 2024-06-05
Results Overview
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition which is temporally associated with the use of the Sponsor's product, was also an AE. The number of participants who experienced an AE was reported for each dose level group.
Recruitment status
COMPLETED
Study phase
PHASE1
Target enrollment
35 participants
Primary outcome timeframe
From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
Results posted on
2024-06-05
Participant Flow
35 participants were enrolled and treated in this study. 14 enrolled into Panel 1 and received MK-5108 monotherapy. An additional 4 enrolled into Panel 1 and received MK-5108 as monotherapy prior to crossing over to Panel 2 and receiving MK-5108 with docetaxel. 17 enrolled into Panel 2 and received only the combination of MK-5108 and docetaxel.
Participant milestones
| Measure |
MK-5108 200 mg BID (Panel 1)
Participants received 200 mg of MK-5108 orally twice daily (BID) the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 400 mg BID (Panel 1)
Participants received 400 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 800 mg BID (Panel 1)
Participants received 800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 1200 mg BID (Panel 1)
Participants received 1200 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 1500 mg BID (Panel 1)
Participants received 1500 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 1800 mg BID (Panel 1)
Participants received 1800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Panel 2)
Participants receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered intravenously (IV) the first 2 days of a 21-day cycle.
|
MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Panel 2)
Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
MK-5108 225 mg BID + 60 mg/m^2 Docetaxel (Panel 2)
Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Crossover)
After receiving treatment in Panel 1, one participant crossed over to Panel 2 per protocol following disease progression to receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Crossover)
After receiving treatment in Panel 1, participants crossed over to Panel 2 per protocol following disease progression to receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Panel 1 + Panel 2
STARTED
|
3
|
3
|
3
|
3
|
3
|
3
|
6
|
6
|
5
|
0
|
0
|
|
Panel 1 + Panel 2
Crossed Over to Panel 2 Due to PD
|
0
|
1
|
0
|
0
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
|
Panel 1 + Panel 2
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Panel 1 + Panel 2
NOT COMPLETED
|
3
|
3
|
3
|
3
|
3
|
3
|
6
|
6
|
5
|
0
|
0
|
|
Crossover Participants
STARTED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
3
|
|
Crossover Participants
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Crossover Participants
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
3
|
Reasons for withdrawal
| Measure |
MK-5108 200 mg BID (Panel 1)
Participants received 200 mg of MK-5108 orally twice daily (BID) the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 400 mg BID (Panel 1)
Participants received 400 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 800 mg BID (Panel 1)
Participants received 800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 1200 mg BID (Panel 1)
Participants received 1200 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 1500 mg BID (Panel 1)
Participants received 1500 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 1800 mg BID (Panel 1)
Participants received 1800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Panel 2)
Participants receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered intravenously (IV) the first 2 days of a 21-day cycle.
|
MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Panel 2)
Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
MK-5108 225 mg BID + 60 mg/m^2 Docetaxel (Panel 2)
Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Crossover)
After receiving treatment in Panel 1, one participant crossed over to Panel 2 per protocol following disease progression to receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Crossover)
After receiving treatment in Panel 1, participants crossed over to Panel 2 per protocol following disease progression to receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Panel 1 + Panel 2
Adverse Event
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
|
Panel 1 + Panel 2
Physician Decision
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
Panel 1 + Panel 2
Progressive Disease (PD)
|
3
|
2
|
2
|
3
|
3
|
3
|
5
|
4
|
4
|
0
|
0
|
|
Panel 1 + Panel 2
Withdrawal by Subject
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
|
Crossover Participants
Progressive Disease
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
|
Crossover Participants
Study Terminated by Sponsor
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
Baseline Characteristics
Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001)
Baseline characteristics by cohort
| Measure |
MK-5108 200 mg BID (Panel 1)
n=3 Participants
Participants received 200 mg of MK-5108 orally twice daily (BID) the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 400 mg BID (Panel 1)
n=3 Participants
Participants received 400 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 800 mg BID (Panel 1)
n=3 Participants
Participants received 800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 1200 mg BID (Panel 1)
n=3 Participants
Participants received 1200 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 1500 mg BID (Panel 1)
n=3 Participants
Participants received 1500 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 1800 mg BID (Panel 1)
n=3 Participants
Participants received 1800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Panel 2)
n=6 Participants
Participants receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered intravenously (IV) the first 2 days of a 21-day cycle.
|
MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Panel 2)
n=6 Participants
Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
MK-5108 225 mg BID + 60 mg/m^2 Docetaxel (Panel 2)
n=5 Participants
Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
Total
n=35 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
54.0 years
STANDARD_DEVIATION 11.4 • n=99 Participants
|
57.0 years
STANDARD_DEVIATION 7.8 • n=107 Participants
|
75.3 years
STANDARD_DEVIATION 9.1 • n=206 Participants
|
58.0 years
STANDARD_DEVIATION 15.7 • n=7 Participants
|
54.3 years
STANDARD_DEVIATION 7.5 • n=31 Participants
|
61.0 years
STANDARD_DEVIATION 2.0 • n=30 Participants
|
58.0 years
STANDARD_DEVIATION 15.1 • n=3 Participants
|
57.3 years
STANDARD_DEVIATION 15.7 • n=6 Participants
|
59.8 years
STANDARD_DEVIATION 8.9 • n=114 Participants
|
59.1 years
STANDARD_DEVIATION 11.9
|
|
Sex: Female, Male
Female
|
2 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
2 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
1 Participants
n=30 Participants
|
4 Participants
n=3 Participants
|
2 Participants
n=6 Participants
|
3 Participants
n=114 Participants
|
15 Participants
|
|
Sex: Female, Male
Male
|
1 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
3 Participants
n=31 Participants
|
2 Participants
n=30 Participants
|
2 Participants
n=3 Participants
|
4 Participants
n=6 Participants
|
2 Participants
n=114 Participants
|
20 Participants
|
PRIMARY outcome
Timeframe: From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)Population: All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition which is temporally associated with the use of the Sponsor's product, was also an AE. The number of participants who experienced an AE was reported for each dose level group.
Outcome measures
| Measure |
MK-5108 200 mg BID (Panel 1)
n=3 Participants
Participants received 200 mg of MK-5108 orally twice daily (BID) the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 400 mg BID (Panel 1)
n=3 Participants
Participants received 400 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 800 mg BID (Panel 1)
n=3 Participants
Participants received 800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 1200 mg BID (Panel 1)
n=3 Participants
Participants received 1200 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 1500 mg BID (Panel 1)
n=3 Participants
Participants received 1500 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 1800 mg BID (Panel 1)
n=3 Participants
Participants received 1800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Panel 2)
n=6 Participants
Participants receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered intravenously (IV) the first 2 days of a 21-day cycle.
|
MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Panel 2)
n=6 Participants
Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
MK-5108 225 mg BID + 60 mg/m^2 Docetaxel (Panel 2)
n=5 Participants
Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Crossover)
n=1 Participants
After receiving treatment in Panel 1, one participant crossed over to Panel 2 per protocol following disease progression to receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Crossover)
n=3 Participants
After receiving treatment in Panel 1, participants crossed over to Panel 2 per protocol following disease progression to receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants Who Experienced an Adverse Event (AE)
|
3 Participants
|
3 Participants
|
3 Participants
|
3 Participants
|
3 Participants
|
3 Participants
|
6 Participants
|
6 Participants
|
5 Participants
|
1 Participants
|
3 Participants
|
PRIMARY outcome
Timeframe: Day 1 to Day 21 of study treatment (Cycle 1 for Panel 1, Panel 2, or Crossover)Population: All participants that received one or more doses of study medication. Participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and DLTs were reported according to treatment received.
DLTs were AEs considered related to study drug that prevented escalation of the drug dose. Hematologic DLTs included any Grade 5 hematologic toxicity, Grade 4 neutropenia lasting for ≥7 days in duration, Grade 3 or Grade 4 neutropenia with fever \>38.5°C and/or infection requiring antibiotic or anti-fungal treatment, and Grade 4 thrombocytopenia (≤25.0 x 10\^9/L). Non-hematologic DLT was defined as any Grade 3, 4, or 5 non-hematologic toxicity, with the specific exceptions of: Grade 3 nausea or Grade 3 vomiting, Grade 3 diarrhea, or Grade 3 dehydration occurring in the setting of inadequate compliance with supportive care and lasting for \<48 hours, alopecia, inadequately treated hypersensitivity reactions, or Grade 3 elevated transaminases of ≤1 week in duration. Any drug-related AE leading to a dose modification of MK-5108, or any unresolved drug-related toxicity persisting\>6 weeks, was also considered a DLT.
Outcome measures
| Measure |
MK-5108 200 mg BID (Panel 1)
n=3 Participants
Participants received 200 mg of MK-5108 orally twice daily (BID) the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 400 mg BID (Panel 1)
n=3 Participants
Participants received 400 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 800 mg BID (Panel 1)
n=3 Participants
Participants received 800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 1200 mg BID (Panel 1)
n=3 Participants
Participants received 1200 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 1500 mg BID (Panel 1)
n=3 Participants
Participants received 1500 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 1800 mg BID (Panel 1)
n=3 Participants
Participants received 1800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Panel 2)
n=6 Participants
Participants receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered intravenously (IV) the first 2 days of a 21-day cycle.
|
MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Panel 2)
n=6 Participants
Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
MK-5108 225 mg BID + 60 mg/m^2 Docetaxel (Panel 2)
n=5 Participants
Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Crossover)
n=1 Participants
After receiving treatment in Panel 1, one participant crossed over to Panel 2 per protocol following disease progression to receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Crossover)
n=3 Participants
After receiving treatment in Panel 1, participants crossed over to Panel 2 per protocol following disease progression to receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Dose Limiting Toxicities (DLTs)
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
Adverse Events
MK-5108 100 mg BID + 60 mg/m2 Docetaxel (Panel 2)
Serious events: 1 serious events
Other events: 5 other events
Deaths: 0 deaths
MK-5108 150 mg BID + 60 mg/m2 Docetaxel (Panel 2)
Serious events: 4 serious events
Other events: 6 other events
Deaths: 0 deaths
MK-5108 225 mg BID + 60 mg/m2 Docetaxel (Panel 2)
Serious events: 4 serious events
Other events: 4 other events
Deaths: 0 deaths
MK-5108 100 mg BID + 60 mg/m2 Docetaxel (Crossover)
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
MK-5108 150 mg BID + 60 mg/m2 Docetaxel (Crossover)
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
MK-5108 200 mg BID (Panel 1)
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
MK-5108 400 mg BID (Panel 1)
Serious events: 1 serious events
Other events: 2 other events
Deaths: 0 deaths
MK-5108 800 mg BID (Panel 1)
Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths
MK-5108 1200 mg BID (Panel 1)
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
MK-5108 1500 mg BID (Panel 1)
Serious events: 1 serious events
Other events: 3 other events
Deaths: 1 deaths
MK-5108 1800 mg BID (Panel 1)
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
MK-5108 100 mg BID + 60 mg/m2 Docetaxel (Panel 2)
n=6 participants at risk
Participants received 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered intravenously (IV) the first 2 days of a 21-day cycle.
|
MK-5108 150 mg BID + 60 mg/m2 Docetaxel (Panel 2)
n=6 participants at risk
Participants received 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
MK-5108 225 mg BID + 60 mg/m2 Docetaxel (Panel 2)
n=5 participants at risk
Participants received 225 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
MK-5108 100 mg BID + 60 mg/m2 Docetaxel (Crossover)
n=1 participants at risk
After receiving treatment in Panel 1, one participant crossed over to Panel 2 per protocol following disease progression to receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
MK-5108 150 mg BID + 60 mg/m2 Docetaxel (Crossover)
n=3 participants at risk
After receiving treatment in Panel 1, participants crossed over to Panel 2 per protocol following disease progression to receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
MK-5108 200 mg BID (Panel 1)
n=3 participants at risk
Participants received 200 mg of MK-5108 orally twice daily (BID) the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 400 mg BID (Panel 1)
n=3 participants at risk
Participants received 400 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 800 mg BID (Panel 1)
n=3 participants at risk
Participants received 800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 1200 mg BID (Panel 1)
n=3 participants at risk
Participants received 1200 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 1500 mg BID (Panel 1)
n=3 participants at risk
Participants received 1500 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 1800 mg BID (Panel 1)
n=3 participants at risk
Participants received 1800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Cardiac disorders
Sinus bradycardia
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Intestinal obstruction
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Infections and infestations
Infection
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm progression
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Nervous system disorders
Syncope
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Psychiatric disorders
Mental status changes
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Skin and subcutaneous tissue disorders
Angioedema
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Vascular disorders
Thrombosis
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
Other adverse events
| Measure |
MK-5108 100 mg BID + 60 mg/m2 Docetaxel (Panel 2)
n=6 participants at risk
Participants received 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered intravenously (IV) the first 2 days of a 21-day cycle.
|
MK-5108 150 mg BID + 60 mg/m2 Docetaxel (Panel 2)
n=6 participants at risk
Participants received 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
MK-5108 225 mg BID + 60 mg/m2 Docetaxel (Panel 2)
n=5 participants at risk
Participants received 225 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
MK-5108 100 mg BID + 60 mg/m2 Docetaxel (Crossover)
n=1 participants at risk
After receiving treatment in Panel 1, one participant crossed over to Panel 2 per protocol following disease progression to receive 100 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
MK-5108 150 mg BID + 60 mg/m2 Docetaxel (Crossover)
n=3 participants at risk
After receiving treatment in Panel 1, participants crossed over to Panel 2 per protocol following disease progression to receive 150 mg of MK-5108 orally BID in combination with 60 mg/m\^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
|
MK-5108 200 mg BID (Panel 1)
n=3 participants at risk
Participants received 200 mg of MK-5108 orally twice daily (BID) the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 400 mg BID (Panel 1)
n=3 participants at risk
Participants received 400 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 800 mg BID (Panel 1)
n=3 participants at risk
Participants received 800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 1200 mg BID (Panel 1)
n=3 participants at risk
Participants received 1200 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 1500 mg BID (Panel 1)
n=3 participants at risk
Participants received 1500 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
MK-5108 1800 mg BID (Panel 1)
n=3 participants at risk
Participants received 1800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Investigations
Glucose urine present
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Blood and lymphatic system disorders
Anaemia
|
33.3%
2/6 • Number of events 6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
83.3%
5/6 • Number of events 9 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
40.0%
2/5 • Number of events 8 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
100.0%
1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Blood and lymphatic system disorders
Leukocytosis
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Blood and lymphatic system disorders
Leukopenia
|
66.7%
4/6 • Number of events 17 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
2/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
60.0%
3/5 • Number of events 8 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Blood and lymphatic system disorders
Lymphadenopathy
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Blood and lymphatic system disorders
Lymphopenia
|
50.0%
3/6 • Number of events 23 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Blood and lymphatic system disorders
Neutropenia
|
66.7%
4/6 • Number of events 12 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
83.3%
5/6 • Number of events 10 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
60.0%
3/5 • Number of events 7 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
16.7%
1/6 • Number of events 7 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Cardiac disorders
Bradycardia
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Cardiac disorders
Pericardial effusion
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Cardiac disorders
Sinus bradycardia
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Ear and labyrinth disorders
Ear discomfort
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Eye disorders
Lacrimation increased
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Eye disorders
Visual impairment
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Abdominal distension
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Abdominal wall cyst
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Cheilitis
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Constipation
|
66.7%
4/6 • Number of events 7 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
100.0%
3/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
100.0%
3/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Diarrhoea
|
33.3%
2/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
2/6 • Number of events 6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
40.0%
2/5 • Number of events 5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
100.0%
1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Dry mouth
|
16.7%
1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Epigastric discomfort
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Faeces discoloured
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Flatulence
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Hypoaesthesia oral
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Nausea
|
66.7%
4/6 • Number of events 7 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
50.0%
3/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
60.0%
3/5 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
100.0%
1/1 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 8 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Oesophagitis
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Oral pain
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Stomatitis
|
16.7%
1/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
4/6 • Number of events 8 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
40.0%
2/5 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
40.0%
2/5 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
100.0%
3/3 • Number of events 7 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
General disorders
Chest pain
|
33.3%
2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
General disorders
Chills
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
General disorders
Fatigue
|
66.7%
4/6 • Number of events 12 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
4/6 • Number of events 7 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
60.0%
3/5 • Number of events 5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
100.0%
3/3 • Number of events 5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
100.0%
3/3 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
General disorders
Influenza like illness
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
General disorders
Infusion related reaction
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
General disorders
Infusion site erythema
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
General disorders
Local swelling
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
100.0%
1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
General disorders
Localised oedema
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
100.0%
1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
General disorders
Non-cardiac chest pain
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
General disorders
Oedema peripheral
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
100.0%
1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
General disorders
Pain
|
16.7%
1/6 • Number of events 5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
General disorders
Puncture site pain
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
General disorders
Pyrexia
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Infections and infestations
Cystitis
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Infections and infestations
Fungal infection
|
16.7%
1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Infections and infestations
Gastroenteritis viral
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Infections and infestations
Mucocutaneous candidiasis
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Infections and infestations
Pharyngitis streptococcal
|
16.7%
1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Injury, poisoning and procedural complications
Incision site complication
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Investigations
Activated partial thromboplastin time prolonged
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Investigations
Alanine aminotransferase increased
|
33.3%
2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Investigations
Aspartate aminotransferase increased
|
50.0%
3/6 • Number of events 5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Investigations
Bilirubin conjugated increased
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Investigations
Blood alkaline phosphatase increased
|
33.3%
2/6 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Investigations
Blood bicarbonate decreased
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Investigations
Blood creatinine increased
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
100.0%
1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Investigations
Blood lactate dehydrogenase increased
|
33.3%
2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Investigations
Blood phosphorus decreased
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Investigations
Blood pressure increased
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Investigations
Blood urine present
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Investigations
Electrocardiogram QT prolonged
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Investigations
Neutrophil count decreased
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Investigations
Prostatic specific antigen increased
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Investigations
Prothrombin time prolonged
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Investigations
Weight decreased
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Investigations
White blood cell count decreased
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
50.0%
3/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
2/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
60.0%
3/5 • Number of events 5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
16.7%
1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
40.0%
2/5 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
66.7%
4/6 • Number of events 11 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
50.0%
3/6 • Number of events 17 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
40.0%
2/5 • Number of events 8 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 10 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 7 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Metabolism and nutrition disorders
Hypermagnesaemia
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Metabolism and nutrition disorders
Hypernatraemia
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
16.7%
1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
40.0%
2/5 • Number of events 6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
100.0%
1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
16.7%
1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
16.7%
1/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
16.7%
1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
16.7%
1/6 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
33.3%
2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Musculoskeletal and connective tissue disorders
Groin pain
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Musculoskeletal and connective tissue disorders
Nodule on extremity
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
33.3%
2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Nervous system disorders
Burning sensation
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
2/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Nervous system disorders
Dysgeusia
|
16.7%
1/6 • Number of events 6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Nervous system disorders
Extrapyramidal disorder
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Nervous system disorders
Headache
|
50.0%
3/6 • Number of events 8 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Nervous system disorders
Hypoaesthesia
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Nervous system disorders
Neuropathy peripheral
|
16.7%
1/6 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Nervous system disorders
Paraesthesia
|
16.7%
1/6 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Nervous system disorders
Parosmia
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
33.3%
2/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Nervous system disorders
Presyncope
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Nervous system disorders
Sinus headache
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Psychiatric disorders
Anxiety
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Psychiatric disorders
Depression
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Psychiatric disorders
Emotional distress
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
100.0%
1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Psychiatric disorders
Insomnia
|
16.7%
1/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
100.0%
1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Psychiatric disorders
Mood swings
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Renal and urinary disorders
Dysuria
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
100.0%
1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Renal and urinary disorders
Pollakiuria
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
100.0%
1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Renal and urinary disorders
Urinary incontinence
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Reproductive system and breast disorders
Breast pain
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Reproductive system and breast disorders
Penile oedema
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
100.0%
1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
100.0%
3/3 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
33.3%
2/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 4 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
40.0%
2/5 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
66.7%
2/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea paroxysmal nocturnal
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Hiccups
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
100.0%
1/1 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal dryness
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
33.3%
2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Orthopnoea
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary artery thrombosis
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinitis allergic
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Skin and subcutaneous tissue disorders
Acne
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
50.0%
3/6 • Number of events 9 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
50.0%
3/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
40.0%
2/5 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Skin and subcutaneous tissue disorders
Increased tendency to bruise
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Skin and subcutaneous tissue disorders
Lichenification
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Skin and subcutaneous tissue disorders
Nail disorder
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Skin and subcutaneous tissue disorders
Night sweats
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
2/6 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Skin and subcutaneous tissue disorders
Onychoclasis
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Skin and subcutaneous tissue disorders
Rash
|
16.7%
1/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Skin and subcutaneous tissue disorders
Skin discolouration
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Skin and subcutaneous tissue disorders
Skin disorder
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Skin and subcutaneous tissue disorders
Skin exfoliation
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Skin and subcutaneous tissue disorders
Skin hyperpigmentation
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
16.7%
1/6 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Vascular disorders
Flushing
|
33.3%
2/6 • Number of events 3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/5 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Vascular disorders
Hypotension
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 2 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Vascular disorders
Lymphoedema
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
33.3%
1/3 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
|
Vascular disorders
Phlebitis
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/6 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
20.0%
1/5 • Number of events 1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/1 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
0.00%
0/3 • From Day 1 of study treatment until 30 days following the last dose of study treatment (up to 577 days)
All participants that received one or more doses of study medication. Four participants who received MK-5108 monotherapy in Panel 1 and then crossed over to receive combination treatment in Panel 2 (Crossover) were included in both respective treatment groups and AEs were reported according to treatment received.
|
Additional Information
Senior Vice President, Global Clinical Development
Merck Sharp & Dohme Corp.
Phone: 1-800-672-6372
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.
- Publication restrictions are in place
Restriction type: OTHER